Mean CMT significantly decreased to 341.36±146.26 µm (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients withrecalcitrant diabetic macular edema.Materials and Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasoneimplantation for recalcitrant diabetic macular edema.
📊
Key Findings & Data:Main outcome measures included changes in best corrected visual acuity (BCVA),central macular thickness (CMT), and incidence of ocular side effects.Results: Fifty-seven eyes of thirty-eight patients (20 females, 18 males; mean age 65±7 years) were included in the study.
💡
Conclusion & Impact:Mean CMT significantly decreased to 341.36±146.26 µm (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients withrecalcitrant diabetic macular edema.Materials and Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasoneimplantation for recalcitrant diabetic macular edema. Main outcome measures included changes in best corrected visual acuity (BCVA),central macular thickness (CMT), and incidence of ocular side effects.Results: Fifty-seven eyes of thirty-eight patients (20 females, 18 males; mean age 65±7 years) were included in the study. The meanhemoglobin A1c level was 7.9±1.7%. Before entering the study, patients had undergone 5.71±3.40 anti-vascular endothelial growthfactor (anti-VEGF) and 3.44±2.46 intravitreal triamcinolone acetonide injections. The mean duration of diabetes and diabetic macularedema was 17.2±6.4 years and 60.2±17.6 months, respectively. At baseline, mean CMT was 506.76±166.74 µm, and the mean BCVAwas 0.68±0.38 LogMAR. Mean CMT significantly decreased to 341.36±146.26 µm (p
🔖
Cite This Article
DURUKAN, A. H., AYYILDIZ, Ö., KÜÇÜKEVCİLİOĞLU, M., ERDURMAN, F. C., AKINCIOĞLU, D., AYKAŞ, S. (2022). Outcomes of Intravitreal Dexamethasone Implant in the Treatment of Recalcitrant Diabetic Macular Edema. Türk Oftalmoloji Dergisi, Cilt: 47 - Sayı: 5, 274–278. https://ajindex.com/articles/637863
Guigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matonti F, Prost-Magnin O, Meyer F. Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study. J Fr Ophtalmol. 2014;37:480-485.
Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci. 2011;52:2741-2748.
Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group: Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289-296.
Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-317.
Zucchiatti I, Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, Bandello F. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica. 2012;228:117-122.
Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231:141-146.
Totan Y, Güler E, Gürağaç FB. Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment. Curr Eye Res. 2016;41:107-113.
Zhioua I, Semoun O, Lalloum F, Souied EH. Intravitreal dexamethasone implant in patients with ranibizumab persistent diabetic macular edema. Retina. 2015;35:1429-1435.
Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Threeyear, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904- 1914.
Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009;29:46-51.
Chan CK, Mohamed S, Lee VY, Lai TY, Shanmugam MP, Lam DS. Intravitreal dexamethasone for diabetic macular edema: a pilot study. Ophthalmic Surg Lasers Imaging. 2010;40:26-30.